Research Article

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Benyong Xu,1 Yanhua Mao,2 Xiaoyu Wan,2 Jianhui Chen,1 Meiping Ye,2 Mengling Zhan,1 Liyun Xu,2 Lan Zhao,2 Bing Li,2 Zhemin Zhang2,3, Yang Liu2,3, and Haiqing Chu2,4

1Tongji University School of Medicine, Shanghai 200092, China
2Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
3Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
4Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

Correspondence should be addressed to Yang Liu; yang_liu77@126.com and Haiqing Chu; chu_haiqing@126.com

Received 9 December 2018; Accepted 24 February 2019; Published 10 March 2019

Academic Editor: Jack Kastelik

Copyright © 2019 Benyong Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Factors determining the prognosis of diffuse panbronchiolitis (DPB) remain unclear at present. The objective of this study was to identify the prognostic value of concomitant bronchiectasis in the macrolide treatment efficacy and exacerbation risk in DPB patients.

Methods. Data of patients initially diagnosed with DPB at the Shanghai Pulmonary Hospital between January 2007 and December 2017 were retrospectively collected and analyzed. The patients were divided into two groups according to the existence of bronchiectasis. Clinical manifestations, laboratory findings, microbiological culture results, as well as exacerbation risks and treatment outcomes, were compared between these two groups. The survival curve and Cox regression analysis models were additionally constructed to further demonstrate the predicting role of bronchiectasis in DPB exacerbation.

Results. Baseline data revealed more respiratory symptoms, lower body mass index (BMI), and forced expiratory volume in one second (FEV1) as well as increased isolates of Pseudomonas aeruginosa (P. aeruginosa) in DPB subjects with bronchiectasis than those without. Furthermore, bronchiectasis was associated with a lower rate of responsiveness to macrolides and increased exacerbation frequency during follow-up. The survival curve and Cox regression analysis showed that comorbid bronchiectasis was linked to increased time to episode relapse, which remained significant even after controlling for BMI, FEV1, and P. aeruginosa culture results.

Conclusion. The coexistence of bronchiectasis predicted a poor outcome of maintenance macrolide therapy and an increased exacerbation risk in DPB subjects, possibly through its impacts on nutritional status, pulmonary function, and P. aeruginosa infections.

1. Introduction

Diffuse panbronchiolitis (DPB) is an idiopathic inflammatory disease, which affects the distal airways and predominantly the transition zone between the respiratory bronchioles and alveoli [1]. It is characterized by progressive suppurative and obstructive airway disease. If left untreated, DPB will progress to bronchiectasis, respiratory failure, and eventually death [2]. The prognosis of DPB was poor before the long-term treatment with erythromycin was introduced. Since then, the 10-year survival rate has improved from 33.2% to 90% [3]. However, there are still cases in which the benefit is minimal and the disease relapses or progresses in spite of causes of macrolide antibiotics treatment. The factors that affect treatment efficacy and relapse are still unknown [4, 5].

Bronchiectasis is a chronic lung disease characterized by a vicious cycle of airway infection and inflammation, leading
to permanent structural damage to the small airways and sometimes to the surrounding lung parenchyma [6]. The clinical presentation can overlap with other respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea-hypopnea syndrome (OSAHS), and so on, forming overlap syndromes [7–9]. Recently, several reports indicated that comorbid bronchiectasis was associated with poorer treatment efficacy and prognosis for various other chronic lung diseases. Bronchiectasis comorbidity also resulted in increased frequency of cases with difficult-to-treat pathogenic bacteria, decreased lung function, and increased risk of death from all causes, among other symptoms [10, 11]. DPB has a very well-established relationship with bronchiectasis. DPB can occur in conjunction with bronchiectasis or progress to severe bronchiectasis in its advanced stage. Bronchiectasis in conjunction with DPB has been assumed a more severe syndrome in DPB. However, this conclusion was mainly based on clinical observations and expert opinions. Confirmation and detailed data from systematic clinical research are still lacking.

We hypothesized that bronchiectasis would be a negative factor for DPB treatment and exacerbation risk, similar to its role in other chronic lung diseases. Therefore, we conducted a retrospective cohort study to identify the prognostic value of bronchiectasis in DPB, with the underlying mechanisms explored.

2. Patients and Methods

2.1. Patients and Data Collection. Data of 395 cases with initially suspected DPB from 2007 to 2017, who were then prescribed a macrolide regimen and asked for follow-up on a regular basis, were retrospectively screened and collected from the Shanghai Pulmonary Hospital. Among them, 217 were finally enrolled into the cohort, following the flow chart for selecting the eligible patients that is shown in Figure 1. All patients were well documented with detailed clinical information, including baseline demographic data, arterial blood gas analysis, blood cold hemagglutination (CHA) testing, pulmonary function tests, and microbiological and laboratory results of sputum and bronchial lavage fluid. The radiological findings were also required, with all patients presented typical bilateral diffused tree-in-bud patterns. Lung biopsy was performed in 10 cases, all of which were pathologically consistent with DPB. During the follow-up period, information on treatment efficacy and exacerbation frequency was collected and assessed. Patients were divided into two groups according to the existence of bronchiectasis in chest CT scan images, except for which no meaningful differences were found. The study was approved by the Ethical Committee of Tongji University, Shanghai Pulmonary Hospital. All of the participants signed informed consent for any procedures that were relevant to this study.

2.2. Diagnostic Criteria of DPB and Bronchiectasis. The DPB diagnostic criteria were in accordance with the guidelines proposed by a working group of the Ministry of Health and Welfare of Japan [12]. A chest high-resolution computed tomography (HRCT) scan was used to confirm the diagnosis of bronchiectasis, based on the diagnostic criteria proposed by Naidich et al. [13]. Cases with small bronchiectasis that was only visible in a single pulmonary segment, which also can be detected in healthy people, were excluded. Patients with bronchiectasis caused by congenital diseases such as cystic fibrosis and Marfan syndrome were not found in this study.

2.3. Assessment of Treatment Efficacy. The treatment strategy was a combination of macrolide antibiotics and other measures, including glucocorticoids, antibiotics against infectious pathogens, oxygen therapy, symptomatic and supportive therapy, etc [2, 12, 14]. The patient’s response to macrolide antibiotics treatment was defined as follows [15]: (1) Healed: all symptoms and abnormal body signs disappeared; chest CT, arterial blood gas analysis, and lung function returned to normal. (2) Improved: more than one of the clinical symptoms, body signs, or imaging scan improved after treatment. (3) Unchanged: clinical symptoms and abnormal body signs persisted with no improvement observed in the chest CT. (4) Deteriorating: one or more clinical symptoms, abnormal body signs, or chest CT were aggravated/became worse. (5) Recurrent: healed after treatment, but clinical or radiological regression occurred during follow-up. Conditions (1) or (2) was considered as responsive. Conditions (3), (4), and (5) were considered as unresponsive. The symptoms and body signs were documented in the medical records. CT images were analyzed and interpreted by two radiologists and a pulmonologist who were blinded to the case. The medical records and radiological reports were evaluated by two pulmonologists to confirm the accuracy of the extracted information.

2.4. Definition of DPB Exacerbations. An exacerbation of DPB was defined, in our study, as the presence for at least 24h of increased symptoms (including cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, he- moptyis), with or without an increase in tree-in-bud in CT
scans, resulting in an unscheduled clinical visit and a subsequent hospital admission.

2.5. Statistical Analysis. Statistical analysis was carried using SPSS version 20 (IBM Corporation, Chicago, IL, USA). Group comparisons for continuous data were performed using either Student’s t-test (normally distributed data) or Mann–Whitney U test (nonparametric distributed data). Group comparisons of proportions were made using Pearson’s chi-squared test or Fisher’s exact test. The survival curve of the time to exacerbation for the two groups (i.e., DPB patients with and without bronchiectasis) was constructed according to the Kaplan–Meier method and was compared using the log-rank test. A multivariate stepwise Cox regression analysis was performed until the most parsimonious model was achieved to assess the association between the concomitant bronchiectasis and the time to exacerbation after initial DPB diagnosis and beginning of macrolides treatment, adjusting for age, gender, BMI, smoking status, disease duration, chronic sinusitis, CHA test, FEV1, and respiratory tract cultures for P. aeruginosa. The confounders were either of clinical interest or were selected from the demographic, clinical, and experimental findings as well as therapeutic regimens, listed in Tables 1 and 2, through a univariate Cox regression analysis, with factors with a P value of <0.1 entering into the final analysis. P values of <0.05 were considered statistically significant.

3. Results

3.1. Baseline Demographic, Clinical, and Laboratory Findings between DPB Patients with and without Bronchiectasis. A total of 217 from 395 DPB patients were included into the final analysis. Bronchiectasis was present in 129 patients. The baseline characteristics for all patients are shown in Table 1. DPB patients with bronchiectasis demonstrated significantly lower BMI than those without bronchiectasis (P < 0.001). No significant difference in age, sex, smoking status, personal history, and previous disease history existed between the two groups.

There was a weak trend towards a longer DPB duration in patients with bronchiectasis (P = 0.088). Cough (100%), sputum production (95%), exertional dyspnea (89.4%), and shortness of breath (76.5%) were the most common symptoms in each group, followed by hemoptysis (23.0%) and body weight loss (15.2%). More patients in the bronchiectasis group suffered from short breath (P < 0.001), hemoptysis (P = 0.039), and body weight loss (P = 0.038).

Arterial blood gas analysis showed a lower level of arterial partial pressure of oxygen (PaO2) in DPB subjects with bronchiectasis (P = 0.037). No significant differences in blood CHA test, white blood cell count, neutrophil percentages, C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR) were found between the two groups.

Both groups exhibited damaged pulmonary functions, which were more pronounced in the DPB subjects with bronchiectasis, as reflected by lower levels of forced expiratory volume in one second (FEV1, P = 0.040), forced vital capacity (FVC, P = 0.058), and FEV1/FVC (P = 0.070), with the former reaching statistical significance. No difference in forced expiratory flow 75% (FEF75) and residual volume (RV) was found.

Pseudomonas aeruginosa (P. aeruginosa) was the most frequently detected pathogenic bacteria (35.5%) in all the subjects, followed by Haemophilus influenzae (15.7%), Candida albicans (8.8%), and Neisseria bacteria (7.4%). Only P. aeruginosa was more frequently isolated in DPB patients with bronchiectasis (P < 0.001).

3.2. Follow-Up Outcomes between DPB Patients with and without Bronchiectasis. Therapeutic regimens and efficacy assessments are shown in Table 2. There were no differences in the selection of macrolide antibiotics and regular use of other auxiliary medicines, including inhaled corticosteroid (ICS), long-acting bronchial agonist (LABA), and long-acting muscarinic antagonist (LAMA). DPB patients with bronchiectasis experienced more aggravating events (P = 0.048). The rate of responsiveness (healed plus improved) was significantly lower in DPB patients with bronchiectasis than those without (P < 0.001).

The Kaplan–Meier survival and log-rank test results showed a significant difference in the time to exacerbation after the beginning of macrolide therapy between patients with and without bronchiectasis (P < 0.001), with the estimated value of 20.0 (95% CI: 17.6–22.4) months and 29.0 (95% CI: 21.7–36.3) months, respectively (Figure 2). Further analysis via Cox regression analysis revealed bronchiectasis as an independent factor. The unadjusted odds ratio (OR) of 2.121 (95% CI: 1.437–3.131, P < 0.001) remained statistically significant after correction for confounders, including BMI, FEV1, and positive P. aeruginosa isolates (OR 1.545 (95% CI: 1.016–2.349, P = 0.042)) (Table 3).

4. Discussion

In this paper, we conducted a relatively large retrospective cohort study, enrolling 217 subjects. To our knowledge, no other study in the literature has surpassed this case number. Our study also captured data from a long follow-up duration (up to 87 months) to confirm the potential adverse impact of comorbid bronchiectasis in newly diagnosed DPB patients on the efficacy of macrolide maintenance therapy and the exacerbation risk. As expected, our results demonstrated a poorer outcome of macrolide treatment, as well as a shorter period to episode relapse and increased exacerbation frequency since study enrollment in newly diagnosed DPB patients with bronchiectasis compared with their bronchiectasis-free counterparts. Meanwhile, bronchiectasis was also associated with accelerated chronic wasting, more symptoms, poorer lung function, and increased isolates of P. aeruginosa at baseline. According to the multiple Cox regression analysis, comorbid bronchiectasis (in combination with a couple of other clinically significant confounding variables including BMI, FEV1, and positive
P. aeruginosa culture) was a strong independent factor of macrolide treatment. It could thus be speculated that bronchiectasis exerts a detrimental influence on DPB disease control and prognosis, at least through pathways involving nutritional condition, pulmonary function, and lower airway tract infections.

### Table 1: Demographic, clinical, and laboratory findings of DPB subjects with and without bronchiectasis at baseline.

| Parameter                           | Whole group (n = 217) | DPB with bronchiectasis (n = 129) | DPB without bronchiectasis (n = 88) | P value
|-------------------------------------|-----------------------|-----------------------------------|-------------------------------------|---------|
| Age (years)                        | 52.5 ± 16.8           | 53.0 ± 16.6                       | 51.9 ± 17.3                        | 0.597   |
| Female                             | 91 (41.9)             | 59 (45.7)                         | 32 (36.4)                          | 0.108   |
| BMI (kg/m²)                        | **21.3 ± 5.3**        | **19.7 ± 3.9**                    | **23.8 ± 6.2**                     | <0.001  |
| Smoking history                    | 52 (24.0)             | 34 (26.4)                         | 18 (20.5)                          | 0.317   |
| Disease duration (year)            | 7.0 (5.0, 9.0)        | 7.0 (5.0, 10.5)                   | 6.5 (5.0, 9.0)                     | 0.088   |
| Disease history                    |                       |                                   |                                     |         |
| Chronic sinusitis                  | 197 (90.8)            | 116 (89.9)                        | 81 (92.0)                          | 0.596   |
| Chronic bronchitis                 | 19 (8.8)              | 14 (10.9)                         | 5 (5.7)                            | 0.186   |
| Emphysema                          | 11 (5.1)              | 7 (5.4)                           | 4 (4.5)                            | 0.771   |
| Pneumocystosis tuberculosis       | 24 (11.1)             | 17 (13.2)                         | 7 (8.0)                            | 0.228   |
| Hypertension                       | 42 (19.4)             | 23 (17.8)                         | 19 (21.6)                          | 0.491   |
| Diabetes                           | 10 (4.6)              | 6 (4.7)                           | 4 (4.5)                            | 0.971   |
| Cardiovascular diseases            | 14 (6.5)              | 9 (7.0)                           | 5 (5.7)                            | 0.703   |
| Rheumatic diseases                 | 10 (4.6)              | 6 (4.7)                           | 4 (4.5)                            | 0.971   |
| Pulmonary surgery history          | 9 (4.1)               | 7 (5.4)                           | 2 (2.3)                            | 0.253   |
| Clinical manifestations            |                       |                                   |                                     |         |
| Cough                              | 217 (100)             | 129 (100)                         | 88 (100)                           | 1.000   |
| Sputum production                  | 216 (99.5)            | 129 (100)                         | 87 (98.9)                          | 1.000   |
| Shortness of breath                | **166 (76.5)**        | **112 (86.82)**                   | **54 (61.4)**                      | <0.001  |
| Exertional dyspnea                 | 194 (89.4)            | 118 (86.82)                       | 76 (86.4)                          | 0.230   |
| Hemoptysis                         | 50 (23.0)             | 36 (27.9)                         | 14 (15.9)                          | 0.039   |
| Body weight loss                   | 33 (15.2)             | 25 (19.4)                         | 8 (9.1)                            | 0.038   |
| Crackle                            | 119 (54.8)            | 72 (55.8)                         | 47 (53.4)                          | 0.727   |
| Wheezing                           | 53 (24.4)             | 30 (23.3)                         | 23 (26.1)                          | 0.628   |
| Laboratory findings                |                       |                                   |                                     |         |
| pH                                 | 7.41 (7.39, 7.43)     | 7.41 (7.39, 7.43)                 | 7.41 (7.39, 7.43)                  | 0.674   |
| \(P_aCO_2\) (mmHg)                 | 40.7 (37.2, 45.3)     | 40.8 (37.1, 45.6)                 | 40.5 (38.0, 44.7)                  | 0.865   |
| \(P_aO_2\) (mmHg)                  | **80.0 ± 15.7**       | **78.2 ± 14.7**                   | **82.7 ± 16.8**                    | **0.037**|
| WBC (10 × 9/L)                     | 7.6 ± 2.7             | 7.3 ± 2.6                         | 7.9 ± 2.7                          | 0.143   |
| Neutrophil (%)                     | 63.3 ± 11.7           | 64.3 ± 11.4                       | 61.9 ± 11.9                        | 0.134   |
| CRP (mg/L)                         | 4.8 (1.6, 12.4)       | 4.6 (1.6, 15.0)                   | 5.5 (1.5, 11.7)                    | 0.687   |
| ESR (mm/h)                         | 20.2 (9.2, 36.7)      | 19.6 (8.0, 35.4)                  | 20.4 (10.3, 37.4)                  | 0.522   |
| Positive CHA test                  | 49 (22.6)             | 30 (23.3)                         | 19 (21.6)                          | 0.773   |
| Pulmonary function tests           |                       |                                   |                                     |         |
| FVC (% pred)                       | 74.8 ± 20.6           | 72.6 ± 20.9                       | 78.0 ± 19.9                        | 0.058   |
| \(FEV_1\) (% pred)                 | **60.7 ± 15.4**       | **58.9 ± 14.1**                   | **63.3 ± 16.8**                    | **0.040**|
| \(FEV_1/FVC\)                      | 65.0 ± 8.1            | 64.1 ± 7.4                        | 66.2 ± 8.9                         | 0.070   |
| \(FEF75\) (% pred)                 | 39.8 (32.6, 55.9)     | 38.2 (34.1, 54.5)                 | 41.4 (29.3, 57.5)                  | 0.712   |
| RV (% pred)                        | 149.4 (123.3, 178.5)  | 152.6 (125.8, 181.6)              | 145.6 (121.3, 171.0)               | 0.213   |
| Microorganisms                     |                       |                                   |                                     |         |
| Pseudomonas aeruginosa             | 77 (35.5)             | 58 (45.0)                         | 19 (21.6)                          | <0.001  |
| Haemophilus influenzae             | 34 (15.7)             | 22 (17.1)                         | 12 (13.6)                          | 0.496   |
| Non-tuberculous mycobacterium     | 8 (3.7)               | 5 (3.9)                           | 3 (3.4)                            | 1.000   |
| Streptococcus viridans             | 3 (1.4)               | 3 (2.3)                           | 0 (0)                              | 0.273   |
| Candida albicans                   | 19 (8.8)              | 8 (6.2)                           | 11 (12.5)                          | 0.107   |
| Acinetobacter baumannii            | 5 (2.3)               | 5 (3.9)                           | 0 (0)                              | 0.082   |
| Neisseria bacteria                 | 16 (7.4)              | 6 (4.7)                           | 10 (11.4)                          | 0.063   |
| Klebsiella pneumonia               | 2 (0.9)               | 2 (1.6)                           | 0 (0)                              | 0.516   |
| Enterobacter cloacae               | 4 (1.8)               | 2 (1.6)                           | 2 (2.3)                            | 1.000   |

Data are presented as mean ± standard deviation, median (interquartile range), or numbers (percentages). BMI: body mass index; CHA: cold hemaglutination; CI: confidence interval; CRP: C-reactive protein; DPB: diffuse panbronchiolitis; ESR: erythrocyte sedimentation rate; FEV\(_1\): forced expiratory volume in 1 second; FVC: forced vital capacity; OR: odds ratio; \(P_aCO_2\): arterial pressure of carbon dioxide; \(P_aO_2\): arterial pressure of oxygen; pH: potential of hydrogen; RV: residual volume; WBC: white blood cell. ※Disease duration was defined as the time from the first DPB symptoms onset to the first visit to hospital. ▲Comparison of DPB subjects with and without bronchiectasis. ■A positive CHA test was defined as a value greater than 1:64.
**Table 2: Medications, therapeutic effects, and exacerbation frequencies in DPB subjects with and without bronchiectasis during follow-up.**

| Treatment and outcome | Whole group \( (n = 217) \) | DPB with Bronchiectasis \( (n = 129) \) | DPB without Bronchiectasis \( (n = 88) \) | \( P \) value<sup>▲</sup> |
|-----------------------|-------------------------------|---------------------------------|---------------------------------|--------------------------|
| **Macrolide antibiotics** |                               |                                 |                                 |                          |
| Azithromycin          | 179 (82.5)                    | 104 (80.6)                      | 75 (85.2)                       | 0.572                   |
| Clarithromycin        | 23 (10.6)                     | 15 (11.6)                      | 8 (9.1)                         |                         |
| Erythromycin          | 12 (5.5)                      | 7 (5.4)                        | 5 (5.7)                         |                         |
| Roxithromycin         | 3 (1.4)                       | 3 (2.3)                        | 0 (0)                           |                         |
| Regular ICS + LABA    | 35 (16.1)                     | 18 (14.0)                      | 17 (19.3)                       | 0.291                   |
| Regular LAMA          | 28 (12.9)                     | 18 (14.0)                      | 10 (11.4)                       | 0.576                   |
| Follow-up period (months) | 32.0 (18.5, 41.0)             | 35.5 (16.0, 45.0)              | 29.0 (21.0, 39.0)               |                         |
| Exacerbation frequency (time/year)<sup>■</sup> | 0.5 (0, 1.5) | 0.7 (0, 1.6) | 0.3 (0, 1.3) | 0.048                 |
| **Treatment efficacy** |                               |                                 |                                 | <0.001                  |
| Healed                | 36 (16.6)                     | 18 (20.5)                      | 18 (14.0)                       |                         |
| Improved              | 102 (47.0)                    | 53 (60.2)                      | 49 (38.0)                       |                         |
| Unchanged             | 39 (18.0)                     | 6 (6.8)                        | 33 (25.6)                       |                         |
| Deteriorating         | 32 (14.7)                     | 7 (8.0)                        | 25 (19.4)                       |                         |
| Recurrent             | 8 (3.7)                       | 4 (4.5)                        | 4 (3.1)                         |                         |
| **Overall response**  |                               |                                 |                                 | <0.001                  |
| Responsive            | 138 (63.6)                    | 67 (51.9)                      | 71 (80.7)                       |                         |
| Unresponsive          | 79 (36.4)                     | 62 (48.1)                      | 17 (19.3)                       |                         |

Data are presented as median (interquartile range) or numbers (percentages). DPB: diffuse panbronchiolitis; ICS: inhaled corticosteroid; LABA: long-acting bronchial agonist; LAMA: long-acting muscarinic antagonist. <sup>▲</sup>Comparison of DPB subjects with and without bronchiectasis. <sup>■</sup>The exacerbation frequency (time/year) was defined as the number of exacerbation events/duration of follow-up (months) × 12.

---

*P. aeruginosa* is a well-documented pathogen that provokes an intense inflammatory response leading to persistent airway inflammation and airway structural damage [16, 17]. It has been reported that in the early stage of DPB, *Haemophilus influenzae* represents the most common colonized microbiological agent (44%), followed by *P. aeruginosa* (22%). Colonization with *P. aeruginosa* eventually occurs, and the detection rate of *P. aeruginosa* in DPB can rise to 60%. This accelerates disease progression, causing a wide range of severe opportunistic infections [1]. Chronic colonization by *P. aeruginosa* is associated with a greater decline in pulmonary function and more frequent exacerbation and hospitalization as well as increased mortality [18, 19]. Consistently, in our study, occurrence of *P. aeruginosa* was more frequently detected in DPB patients with bronchiectasis and was partly responsible for the poor therapeutic outcomes.

Nutritional status is frequently underestimated due to a lack of awareness by health professionals who deal with different chronic respiratory diseases. However, nutritional abnormalities are highly prevalent in this field, leading to important clinical consequences [20]. It has been reported in COPD patients that those with malnutrition present higher degrees of airway obstruction, perception of dyspnea, and CAT scores while having lower exercise capacity [21, 22]. As for bronchiectasis, fat-free mass depletion is related to increased inflammatory activity [23]. However, there are no published data to our knowledge that refer to the relationship between DPB and malnutrition. Therefore, for the first time, our study presented evidence that lower BMI is linked to likelihood of comorbid bronchiectasis and as such has a negative impact in therapeutic outcome. This link justifies a nutritional intervention in the treatment of DPB. The underlying mechanisms are still unknown. However, it may involve impairment of immunological function and increased susceptibility to and severity of community-acquired pneumonia [24–26]. Weakness of the respiratory muscles may also play a role.

Pulmonary dysfunction could be a natural consequence of long-term chronic airway inflammation and recurrent infectious episodes. In our manuscript, a decrease in pulmonary function, reflected by a lower FEV\textsubscript{1} value, represented a third confounding risk factor in addition to *P. aeruginosa* infection and malnutrition in predicting a...
shortened duration of DPB aggravation since maintenance macrolide therapy. This finding was consistent with the established role of FEV₁ in the assessment and prognosis of asthma and COPD [27, 28]. Notably, no difference in FEF75 was documented in our reports, and in view of the large and small airway involvement of FEV₁ and FEF75, respectively, our results suggested that coexistence of bronchiectasis affected large rather than small airways of DPB patients.

It should be pointed out that concomitant bronchiectasis remained significant in the final Cox regression model, even after adjusting for all of the abovementioned factors, indicating other pathways that are involved in the relationship between bronchiectasis and DPB but were not identified here. However, it is reasonable to assume that the irreversible airway damage, the persistent inflammatory response, and the resulting recurrent infections (features involved in bronchiectasis), which cannot be reversed even with an effective therapy, may help explain the difficulty in treating and the poor prognosis of DPB in combination with bronchiectasis.

Several issues and limitations should be mentioned here. First, bronchiectasis may be considered as a primary or secondary condition, which could not be distinguished during our data collection due to the retrospective nature of this study. Second, since there was a marginal (but not statistically significant) difference in DPB duration between our patients with and without bronchiectasis, it is thus possible that the poorer therapeutic effects and prognosis found in the bronchiectasis group might only represent the consequence of advanced or end-stage DPB. However, we do not think this is the case. By using a multiple Cox regression analysis to predict treatment responsiveness, DPB duration was finally excluded from the model, but bronchiectasis remained a predictor of treatment outcome. In addition, we cannot determine whether the *P. aeruginosa* was a colonizing or infecting bacteria. Furthermore, the virulence and resistance of the bacteria cannot be defined either, which will also affect the treatment efficacy and prognosis.

### Data Availability

The data used to support the findings of this study are included within the article.

### Conflicts of Interest

The authors have no conflicts of interest to declare.

### Authors’ Contributions

Benyong Xu, Yanhua Mao, and Xiaoyu Wan contributed equally to this work.

### Acknowledgments

This project was supported by grants obtained from the National Natural Science Foundation of China (grant nos. 81672063 and 81800003), the Natural Science Foundation of Shanghai Municipal Science and Technology Commission (no. 18ZR1431600), the Medical Guide Program of Shanghai Science and Technology Committee (no. 18411970600), the Key Project of Shanghai Municipal Health and Family Planning Commission (no. 201540367), the Youth Project of Shanghai Municipal Health and Family Planning Commission (no. 20164Y0230), the New Frontier Technology
Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Development Center (no. SHDC12017113), and the Project of Top Clinical Medicine Centers and Key Disciplines Construction in Shanghai (no. 2017ZZ02012).

References

[1] H. Homma, A. Yamanaka, S. Tanimoto et al., “Diffuse panbronchiolitis,” Chest, vol. 83, no. 1, pp. 63–69, 1983.

[2] V. Poletti, G. Casoni, M. Chioli, and M. Zompatori, “Diffuse panbronchiolitis,” European Respiratory Journal, vol. 28, no. 4, pp. 862–871, 2006.

[3] S. Kudoh, A. Azuma, M. Yamamoto, T. Izumi, and M. Ando, “Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 6, pp. 1829–1832, 1998.

[4] H. Matsuura, Y. Yoshida, and Y. Yamaji, “Diffuse panbronchiolitis,” QJM: An International Journal of Medicine, vol. 110, p. 253, 2017.

[5] M.-C. Chuang, Y.-T. Chou, Y.-C. Lin, M.-J. Hsieh, and Y.-H. Tsai, “Diffuse panbronchiolitis—the response and recurrence after erythromycin therapy,” Journal of the Formosan Medical Association, vol. 115, no. 10, pp. 876–882, 2016.

[6] C. Magis-Escurra and M. H. Reijers, “Bronchiectasis,” BMJ Clinical Evidence, vol. 2015, p. 1507, 2015.

[7] K. Dimakou, A. Gousiou, M. Toubmis et al., “Investigation of bronchiectasis in severe uncontrolled asthma,” Clinical Respiratory Journal, vol. 12, no. 3, pp. 1212–1218, 2018.

[8] W.-S. Chung and C.-L. Lin, “Acute respiratory events in patients with bronchiectasis-COPD overlap syndrome: a population-based cohort study,” Respiratory Medicine, vol. 140, pp. 6–10, 2018.

[9] N. S. Faria Júnior, J. J. Urbano, I. R. Santos et al., “Evaluation of obstructive sleep apnea in non-cystic fibrosis bronchiectasis: a cross-sectional study,” PLoS One, vol. 12, no. 10, Article ID e0185413, 2017.

[10] W. W. Labaki and M. K. Han, “Impact of bronchiectasis on the frequency and severity of respiratory exacerbations in COPD,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 13, pp. 2335–2338, 2018.

[11] B. Mao, H. W. Lu, M. H. Li et al., “The existence of bronchiectasis predicts worse prognosis in patients with COPD,” Scientific Reports, vol. 5, no. 1, p. 10961, 2015.

[12] K. Nakata, “Diffuse panbronchiolitis (DPB),” Ryokibetsu Shokogun Shirizu, vol. 23, no. 1, pp. 423–427, 1999.

[13] D. P. Naidich, D. I. McCauley, N. F. Khouri, F. P. Stitik, and S. S. Siegelman, “Computed tomography of bronchiectasis,” Journal of Computer Assisted Tomography, vol. 6, no. 3, pp. 437–444, 1982.

[14] S. Kudoh and N. Keicho, “Diffuse panbronchiolitis,” Clinics in Chest Medicine, vol. 33, no. 2, pp. 297–305, 2012.

[15] H. Li, Y. Zhou, F. Fan et al., “Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases,” Internal Medicine, vol. 50, no. 16, pp. 1663–1669, 2011.

[16] E. Faure, K. Kwong, and D. Nguyen, “Pseudomonas aeruginosa in chronic lung infections: how to adapt within the host!,” Frontiers in Immunology, vol. 9, p. 2416, 2018.

[17] P. A. Flume, J. D. Chalmers, and K. N. Olivier, “Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity,” The Lancet, vol. 392, no. 10150, pp. 880–890, 2018.

[18] M. J. McDonnell, H. R. Jary, A. Perry et al., “Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance,” Respiratory Medicine, vol. 109, no. 6, pp. 716–726, 2015.

[19] S. Finch, M. J. McDonnell, H. Abo-Leyah, S. Aliberti, and J. D. Chalmers, “A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis,” Annals of the American Thoracic Society, vol. 12, no. 11, pp. 1602–1611, 2015.

[20] J. Gea, A. Sancho-Muñoz, and R. Chalela, “Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations,” Journal of Thoracic Disease, vol. 10, no. S12, pp. S1332–S1354, 2018.

[21] B. Mete, E. Pehlivan, G. Gülbaş, and H. Günen, “Prevalence of malnutrition in COPD and its relationship with the parameters related to disease severity,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 13, pp. 3307–3312, 2018.

[22] G. Ayar Karakoç, D. Ernam, Ü. Aka Aktürk, S. Öztas, E. Ögür, and F. Kabadayi, “The evaluation of nutritional status of stable COPD patients and to investigate the effect of nutritional status on perception of dyspnea, exercise capacity, body composition, hospitalisation and life quality,” Tuberkuloz ve Toraks, vol. 64, no. 2, pp. 119–126, 2016.

[23] G. Oliveira, C. Oliveira, I. Gaspar et al., “Fat-free mass depletion and inflammation in patients with bronchiectasis,” Journal of the Academy of Nutrition and Dietetics, vol. 112, no. 12, pp. 1999–2006, 2012.

[24] Y. Mitani, Y. Oki, Y Fujimoto et al., “Relationship between functional independence measure and geriatric nutritional risk index in pneumonia patients in long-term nursing care facilities,” Geriatrics & Gerontology International, vol. 17, pp. 1617–1622, 2017.

[25] A. F. Simonetti, D. Viasus, C. Garcia-Vidal, and J. Carratalà, “Management of community-acquired pneumonia in older adults,” Therapeutic Advances in Infectious Disease, vol. 12, no. 1, pp. 3–16, 2014.

[26] N. Akuzawa and H. Naito, “Nutritional parameters affecting severity of pneumonia and length of hospital stay in patients with pneumococcal pneumonia: a retrospective cross-sectional study,” BMC Pulmonary Medicine, vol. 15, no. 1, p. 149, 2015.

[27] A. L. Fuhlbrigge, B. T. Kitch, A. D. Paltiel et al., “FEV1 associated with risk of asthma attacks in a pediatric population,” Journal of Allergy and Clinical Immunology, vol. 107, no. 1, pp. 61–67, 2001.

[28] A. D. Zider, X. Wang, R. G. Buhr, W. Sirichana, I. Z. Barjaktarevic, and C. B. Cooper, “Reduced COPD exacerbation risk correlates with improved FEV1,” Chest, vol. 152, no. 3, pp. 494–501, 2017.